Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.
Primary biliary cirrhosis (PBC) is a presumed autoimmune disease of the liver, which predominantly affects women once over the age of 20 years. Most cases are diagnosed when asymptomatic (60%). The antimitochondrial antibody is present in serum in most, but not in all, patients with PBC. The disease generally progresses slowly but survival is less than an age- and gender-matched general population. The symptomatic patient may have fatigue, generalized pruritus, portal hypertension, osteoporosis, skin xanthomata, fat soluble vitamin deficiencies, and/or recurrent asymptomatic urinary tract infections. Many nonhepatic autoimmune diseases are found in association with PBC and may prompt initial presentation. To date, immunosuppressive therapy has not been shown to prolong survival in PBC. The hydrophilic bile acid, ursodeoxycholic acid (UDCA), has been shown when given in a dose of 13 to 15 mg/kg daily for up to 4 years to delay the time to liver transplantation or death. This therapy also causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders. Treatment with UDCA does not obviate the need for liver transplantation. Therapies to prevent complications arising from malabsorption, portal hypertension, and/or osteoporosis are required as well. Good control of pruritus can be achieved in most patients. PBC is diagnosed with increasing frequency, but the agent(s) responsible for this slowly progressive destruction of the interlobular bile ducts remains elusive and hence a specific therapy remains unavailable.
Heathcote
E J
EJ
Division of Gastroenterology, University of Toronto, The Toronto Hospital, Toronto, Ontario, Canada. jheathcote@msn.com
D001323:Autoantibodies / Q000097:blood; D001706:Biopsy; D006801:Humans; D006932:Hyperbilirubinemia / Q000209:etiology; D006937:Hypercholesterolemia / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D016031:Liver Transplantation; D008928:Mitochondria / Q000276:immunology; D010024:Osteoporosis / Q000209:etiology / Q000628:therapy; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid